Skip to main content

Table 2 All registered variables

From: The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial)

Baseline

Every 3 months

Additionally at 0, 1, 2, 3 years

0 and 2 years (n = 50)

Date of birth

Sex

Height

Smoking

Number of pack years

Primary kidney disease

Previous dialysis

Transplantation date

Number of previous transplantations

Comorbidity

Apoplexia

Myocardial infarction/cardiac revascularisation

Heart failure

Hypertension

Diabetes

Other

Current medication

Symptoms

Dizziness

Fainting

Shortness of breath

Gynecomasty

Impotence

Others

Objective findings

Blood pressure (systolic)

Blood pressure (diastolic)

Pulse

Bodyweight

Blood samples

Sodium

Potassium

Creatinine

Adverse events

Compliance to study drug

Objective findings

Heart stethoscopy

Lung stethoscopy

Edema

ECG

Chrome-EDTA clearance

Blood samples

CRP

Total cholesterol

HDL

LDL

Triglyceride

Markers of fibrosis

24 h urine sample

Creatinine clearance

Proteinuria

U-sodium

U-potassium

Markers of fibrosis

Ambulatory blood pressure

SBP

DBP

SBP-day

SPB-night

DBP-day

DBP-night

Average pulse

Kidney biopsy

Amount of fibrosis (%)

Banff-score

  1. ECG Electrocardiogram, CRP C-reactive protein, HDL High density lipoprotein, LDL Low density lipoprotein, SBP Systolic blood pressure, DBP Diastolic blood pressure